The global Med Tech market is projected to grow at a rate of 4.4% annually, making it one of the fastest developing industry sectors. The stage is set for Singapore to grow into a vibrant, global Med Tech hub with an industry-ready workforce, “plug and play” infrastructure, and the growth of public-private partnerships, along with considerable government support.
For example, SPRING Singapore runs a $40 million Biomedical Sciences Accelerator (BSA) programme to support new Med Tech companies. The Singapore-Stanford Biodesign programme is training the next generation of Med Tech innovators. Dedicated infrastructure in the form of MedTech1, a 9-story 38,000sqm facility, is set to open in Q1 2014 and will provide ready-built space to the industry.
Singapore’s local Med Tech sector has already been reported to include more than 30 companies that have contributed S$4.3 billion in manufacturing output in 2011 for regional and global markets. New implantable devices such as drug-eluting or resorbable heart stents and robotic rehabilitation aids have been reported to boost healthcare productivity.
Are you in the Med Tech industry and want to learn about what investors are looking for?
Are you a young scientist keen on Med Tech and want to be inspired by successful innovators?
Baffled by regulatory processes and want a regulator to walk you through the ins and outs?
OBR-Singapore brings you a series of short talks by key opinion figures in the Singapore Med Tech industry. Covering how to find funding, what investors are looking for, tips from an innovator entrepreneur, how to navigate Asia’s regulatory landscape and how to get started, come spend an informative evening with us and other like-minded individuals in the community.
6:30 – 7:00 PM Registration
7:00 – 7:10 PM OBR & Speaker Introduction
7:10 – 8:30 PM Lecture Series and Q&A
8:30 – 9:30 PM Networking Reception
Prof. Lawrence Ho
Mr. Peh Ruey Feng
Director, Singapore-Stanford Biodesign Programme
Ms. Tan Ming Hao
Experienced trainer in Singapore medical device regulations
Dr. Kevin Koh
Partner, MZ Advisory